Category Archives: Non classé

Our results support considering the clinical evaluation of favipiravir against Zika virus but they advocate against its use against SARS-CoV-2 infection. Our models of SARS-CoV-2 infection in reconstituted Human Airway Epithelium (MucilAir) were predictive again of the results obtained in the cynomolgus NHP model, demonstrating that favipiravir, even at doses up to 600 μM, has no antiviral efficacy against SARS-CoV-2.  Although our results are in contradiction with those obtained in...

The aim of this partnership is to develop innovative experimental methodologies and ambitious logistics for evaluating air treatment technologies and devices in atmospheres contaminated by complex infectious microbiological and virological mixtures. In particular, this Alliance will make it possible to develop mobile and deployable test benches of very large volume (up to 50 m3), enabling the implementation of experimental protocols reproducing real environmental conditions (classrooms, clean ro...

The aim of this strategic and commercial partnership is to address the major health, economic and societal challenges caused by environmental pollution of indoor air and confined spaces. CONIDIA and VirexpR are combining their respective expertise and logistics to offer a new range of services for assessing the performance of air treatment and respiratory protection technologies and devices in atmospheres contaminated by complex infectious microbiologic and virologic mixtures. This partnership w...

Virnext and VirPath laboratory are proud to be associated with Axo Science and EPIMOD companies as part of the SurVir public-private consortium, which aims to develop an automated platform for rapid detection of a wide range of respiratory pathogenic viruses. This public-private consortium has validated an initial proof of concept on various influenza A/B viruses and the Omicron variant of the SARS-CoV-2 virus. The second phase of the research programm will now be implemented in our BSL-2 and BS...

Cynbiose and VirNext have joined forces to offer a unique and innovative preclinical package of services for the evaluation of drugs, vaccines and antibodies candidates against (re)-emergent respiratory viruses, from in vitro screening to in vivo efficacy models of infections, including large animals. On the basis of a public-private partnership initiated in 2017, we have contributed to the evaluation of hundreds of candidates for respiratory viruses, including SARSCoV2 variants, cell lines, rec...

This is a major first step in our collaborative project OZONE, accredited by the Lyonbiopôle healthcare cluster and the TECHTERA cluster for the textile industry in France, and winner of the R&D booster 2021 call for projects, supported by the Auvergne-Rhône-Alpes Regional Innovation Fund and Bpifrance. The second phase of the programme will be implemented in our BSL-2 and BSL-3 laboratories within Lyonbiopôle's Centre Innovation. This collaborative academic and industrial project, in...

We report the antiviral activity of 95 single compounds from the Medicines for Malaria Venture (MVV) and the Calibr ReFRAME drug libraries and 30 combinations with the orally bioactive RdRp inhibitor molnupiravir against SARSCoV2. We performed this standardized medium-throughput screening by using the physiologically relevant reconstituted human airway epithelia MucilAir model (Epithelix), facilitating both reproducibility of results and a clear distinction between antiviral and toxic effects of...

Created 3 months ago with the support of Lyon Ingénierie Projet and EZUS Lyon, VirexpR is specialized in the generation of atmospheres contaminated by respiratory viruses or complex mixtures of infectious pathogens in test benches dedicated to the experimental evaluation of air treatment and respiratory protection technologies and devices. This alliance with the TERA Group, a company listed on the stock exchange (Euronext Growth) and internationally recognized as a major player in real-time air...

Innobiovir is dedicated to research, services and training in the bioproduction and pharmaceutical formulation of viral antigens and biopharmaceuticals. Innobiovir is an alliance between our Virnext Technological Research platform, the VirPath laboratory, the Laboratoire d'Automatique de GEnie des Procédés et de génie Pharmaceutique (LAGEPP, CNRS - UCBL1), the Institut de Pharmacie Industrielle de Lyon (IPIL - ISPB) and the Biological Engineering department of the IUT Lyon 1 (UCBL1). The plat...

Virnext is very proud of its spin-off Vaxxel, which has raised €1.2m to support the development of its bivalent intranasal vaccine candidate against bronchiolitis and severe viral pneumonia. This is excellent recognition of the METAVAC® polyvalent viral vaccine platform developed by VirPath laboratory and Technology Research platform Virnext in partnership with Dr Guy Boivin's team (Centre de recherche du CHU de Québec-Université Laval) and transferred to Vaxxel for the pharmaceutical devel...